ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Liraglutide (Liraglutide STADA)

Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise

CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · STADA Arzneimittel AG
EU · EU licence (European Commission)

Liraglutide (Ablymico)

Treatment of weight management.

CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · STADA Arzneimittel AG

Research

Psychiatry · JAMA Psychiatry · 2026-09-01

Network meta-analysis of 95 RCTs (5898 antipsychotic-treated patients with schizophrenia spectrum disorders): vs placebo, semaglutide (−10.98 kg), liraglutide (−5.43 kg), topiramate, metformin and exenatide were associated with the largest weight loss (moderate certainty).

Meta-analysisn = 5,898
Stogios et al. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis
Diabetes and endocrinology · Diabetes Care · 2026-02-01

Secondary analysis of GRADE (724 adults with type 2 diabetes on metformin): glucagon measures were not associated with HbA1c ≥7.0%, whereas a 1-SD rise in C-peptide index was associated with 17% lower risk; no clear drug differences on glucagon.

Secondary analysisn = 724
Kahn et al. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.